Equity in access to long-acting injectables in the USA

Affiliations

¹ Weill Institute for Neurosciences, Department of Psychiatry and Behavioral Sciences, Department of Medicine, University of California, San Francisco, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland 94612, CA, USA. Electronic address: carlo.hojilla@alumni.ucsf.edu.
² Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
³ Weill Institute for Neurosciences, Department of Psychiatry and Behavioral Sciences, Department of Medicine, University of California, San Francisco, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland 94612, CA, USA.
⁴ Division of Prevention Science, Department of Medicine, University of California, San Francisco, CA, USA.

J Carlo Hojilla et al. Lancet HIV. 2022 Mar.

. 2022 Mar;9(3):e145-e147.

doi: 10.1016/S2352-3018(22)00031-5. Epub 2022 Feb 4.

¹ Weill Institute for Neurosciences, Department of Psychiatry and Behavioral Sciences, Department of Medicine, University of California, San Francisco, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland 94612, CA, USA. Electronic address: carlo.hojilla@alumni.ucsf.edu.
² Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
³ Weill Institute for Neurosciences, Department of Psychiatry and Behavioral Sciences, Department of Medicine, University of California, San Francisco, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland 94612, CA, USA.
⁴ Division of Prevention Science, Department of Medicine, University of California, San Francisco, CA, USA.

No abstract available

Conflict of interest statement

We declare no competing interests. JCH is supported by a grant from the National Institutes of Health (T32 DA007250).

1. Swindells S, Lutz T, van Zyl L, et al. Long-acting cabotegravir + rilpivirine for HIV-1 treatment: ATLAS week 96 results. AIDS. 2021. doi:10.1097/qad.0000000000003025 - DOI - PMC - PubMed
1. Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021;8(4):e185–e196. doi:10.1016/s2352-3018(20)30340-4 - DOI - PubMed
1. D’Amico R, Orkin C, Morell EB, et al. Safety and efficacy of cabotegravir + rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results. J Int AIDS Soc. 2020. Oct;23 Suppl 7(Suppl 7):e25616. Abstracts from HIV Glasgow – Virtual Conference. doi:/10.1002/jia2.25616 - DOI - PMC - PubMed
1. M S, Beima-SofieKristin HM, et al. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV. AIDS Patient Care STDs. 2019;33(3):104–111. doi:10.1089/apc.2018.0198 - DOI - PMC - PubMed
1. Kanazawa JT, Saberi P, Sauceda JA, Dubé K. The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review. AIDS Res Hum Retroviruses. 2021;37(2):75–88. doi:10.1089/aid.2020.0126 - DOI - PMC - PubMed